title: Expression of Th1 and Th17 cytokines and transcription factors in multiple sclerosis patients: does baseline T-bet mRNA predict the response to interferon-beta treatment?
abstract: We studied the effect of one-year interferon (IFN)-beta treatment on the in vivo mRNA expression of IFN-gamma, interleukin (IL)-17, T-bet and RoR-gammat, on peripheral blood mononuclear cells (PBMC) from 36 multiple sclerosis (MS) patients. In the total MS group, IFN-beta induced decrease in mRNA levels of IFN-gamma and T-bet (p<0.0001), while the levels of IL-17 and RoR-gammat remained similar. In both responders and non-responders, IFN-beta induced significant decrease of IFN-gamma (p<0.0001 and p=0.011, respectively), while decrease in T-bet was detected only in responders (p<0.0001). Higher pre-treatment T-bet allowed prediction of the clinical response in the first year (beta=0.601, p=0.036). Our preliminary findings suggest that T-bet expression might be a potential prognostic marker of treatment response to IFN-beta in MS.
authors.affiliation: Institute of Neurology, Clinical Centre of Serbia, University of Belgrade, Dr Subotica 6, 11000 Belgrade, Serbia. jelena60@eunet.rs
authors.forename: Jelena
authors.initials: J
authors.lastname: Drulovic
authors.forename: Emina
authors.initials: E
authors.lastname: Savic
authors.forename: Tatjana
authors.initials: T
authors.lastname: Pekmezovic
authors.forename: Sarlota
authors.initials: S
authors.lastname: Mesaros
authors.forename: Nebojsa
authors.initials: N
authors.lastname: Stojsavljevic
authors.forename: Irena
authors.initials: I
authors.lastname: Dujmovic-Basuroski
authors.forename: Jelena
authors.initials: J
authors.lastname: Kostic
authors.forename: Vladimir
authors.initials: V
authors.lastname: Vasic
authors.forename: Marija
authors.initials: M
authors.lastname: Mostarica Stojkovic
authors.forename: Dusan
authors.initials: D
authors.lastname: Popadic
mesh_terms: D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000096:biosynthesis; D020381:Interleukin-17 / Q000096:biosynthesis*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D011237:Predictive Value of Tests; D012333:RNA, Messenger / Q000096:biosynthesis*; D018168:Receptors, Retinoic Acid / Q000096:biosynthesis; D011988:Receptors, Thyroid Hormone / Q000096:biosynthesis; D020825:T-Box Domain Proteins / Q000096:biosynthesis / Q000235:genetics*; D014157:Transcription Factors / Q000096:biosynthesis*; D016896:Treatment Outcome; D055815:Young Adult; D000098815:T-bet Transcription Factor
chemical_list: D016207:Cytokines; D020381:Interleukin-17; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D012333:RNA, Messenger; C539900:RORC protein, human; D018168:Receptors, Retinoic Acid; D011988:Receptors, Thyroid Hormone; D020825:T-Box Domain Proteins; D000098815:T-bet Transcription Factor; D014157:Transcription Factors; D016899:Interferon-beta; D007371:Interferon-gamma